In:
The Journal of Immunology, The American Association of Immunologists, Vol. 190, No. 1_Supplement ( 2013-05-01), p. 55.14-55.14
Abstract:
Dengue has neither licensed drugs nor vaccines and Its immunopathogenesis is elusive. The disease is widespread and imposes healthcare, economic and social burden on endemic countries like Malaysia. This study aims to understand and identify clinical and immunological markers of disease. Dengue suspected patients were recruited in 2 hospitals where 77% of the study population was categorized as dengue with warning signs. Diagnosis based solely on clinical symptoms is insufficient. Clinically, platelet counts of dengue patients were low and together with increased vWF and prolonged clotting time, retain thrombocytopenia in dengue as an excellent marker for disease progression but not as a differentiator for patients with and without warning signs. Liver enzymes, ALT and AST, were good indicators for dengue disease progression. Immunogenetically, HLA alleles A*24 and B*57 and A*03 were associated with Chinese, Indians and Malay dengue patients, respectively. Three non-structural proteins were found to be immunodominant via the IFN-γ T cell ELISpot assay while cytokines, TNF-β, MIF, SDF-1α and HGF had differential levels in patients with and without warning signs. Although we did observe any discriminative clinical markers, we detected differential levels of 4 cytokines between the groups of patients, which may, with further studies, serve as predictive markers for dengue patients developing warning signs.
Type of Medium:
Online Resource
ISSN:
0022-1767
,
1550-6606
DOI:
10.4049/jimmunol.190.Supp.55.14
Language:
English
Publisher:
The American Association of Immunologists
Publication Date:
2013
detail.hit.zdb_id:
1475085-5
Bookmarklink